Search News Archives
Special Offers and Promotions
Brochures & Literature
Conferences | Events
Ultimate Control for Immunohistochemistry and in situ Hybridisation
AMSBIO announces the launch of CellMax™ - a new range of high quality, consistent and affordable cell line FFPE slides.
Made using a patent-pending process, CellMax™ Cell Pellet Slides have a highly consistent density and homogeneity across the entire cell pellet block that ensures you get accurate results time after time. Cells are harvested by a proprietary trypsin-free method preserving cell surface antigens and inflicting minimal physical damage that could lead to a loss of biomarkers.
CellMax™ slides produce accurate and reproducible results for immunohistochemistry (IHC) providing confidence in antibody performance during IHC analysis. Using CellMax™ both morphological and biological molecules, including protein and nucleic acid targets, are well preserved offering a reference standard for tissue quality during in situ hybridisation (ISH) analysis.
CellMax™ slides are a renewable source of positive and negative controls, derived from 50 tumour cell lines, suitable for assay development and routine analysis.
Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics and energy industries. AMSBIO is able to draw upon in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. Widely acknowledged as an expert in cell culture, AMSBIO partners with clients in tailoring cell systems to enhance organoid and spheroid type screening outcomes from a technological and cost-effective perspective. Custom services include stable cell line production, CRISPR/Cas9 Genome Editing, lentivirus and adenovirus production, large scale protein production and a comprehensive portfolio of antibody services.